A Phase I Study of SHR-3836 in Patients With Multiple Myeloma

Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Study ID
NCT07490613
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SHR-3836 administered as multiple doses. — DRUG
    * In the dose escalation phase, doses are escalated sequentially from low to high levels. * In the dose expansion phase, one or more selected dose levels are further evaluated.

Study Details

This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).

Key Dates

First listed
Mar 24, 2026
Start date
Jun 2, 2026
Status verified
Mar 2026
Primary completion
Apr 30, 2028
Completion
Apr 30, 2029

Study Design

Enrollment
99 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-3836 for injection

Primary Outcome Measure

Determination of Phase II Dose (RP2D) of SHR-3836 [ Time Frame: 24 months ]

Central Contacts

Find similar trials

Nationwide
Multiple myeloma trialsOncology trialsBlood cancer trials

Related Studies